Status:
COMPLETED
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
Lead Sponsor:
Gilead Sciences
Collaborating Sponsors:
Vir Biotechnology, Inc.
Conditions:
Chronic Hepatitis B
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The primary objectives of this study are to evaluate the safety and tolerability of study treatment(s) (selgantolimod-containing combination therapies) and to evaluate the efficacy of study treatment(...
Eligibility Criteria
Inclusion
- Key
- Willing and able to provide informed consent
- Chronic HBV infection for at least 6 months
- Willing to follow protocol-specified contraception requirement
- Key
Exclusion
- Have extensive fibrosis or cirrhosis in the liver
- Have or had liver cancer (hepatocellular carcinoma)
- Have an autoimmune disease
- Have chronic liver disease other than HBV
- Females who are breastfeeding, pregnant, or who wish to become pregnant during the study
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
August 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 19 2024
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT04891770
Start Date
August 14 2021
End Date
July 19 2024
Last Update
July 24 2025
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Liverpool Hospital
Liverpool, New South Wales, Australia, 2170
2
Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050
3
Aalborg University Hospital
Aalborg, Denmark, DK9000
4
Aarhus University Hospital
Aarhus N, Denmark, 8200